產品詳情
簡單介紹：
Anti-LRFN4抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-LRFN4抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-LRFN4
Cat. Number:
Anti-LRFN4抗體KL-11089R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
LRFN4 is a 635 amino acid single-pass type I membrane protein that belongs to the LRFN family. Containing a fibronectin type-III domain, an Ig-like (immunoglobulin-like) domain, a LRRCT domain, a LRRNT domain and seven LRR (leucine-rich) repeats, LRFN4 is thought to promote neurite outgrowth in hippocampal neurons Anti-LRFN4抗體and may play a role in redistributing PSD-95 to the cell periphery. LRFN4 forms heteromeric complexes with LRFN1, LRFN2, LFRN3 and LFRN5, but does not have the ability to form homomeric complexes across cell junctions of adjacent cells like some other LRFN family members. The PDZ-binding motif of LRFN4 is required for neurite outgrowth promotion and for SAP 97-, NE-dlg- and PSD-95-binding. LRFN4 is encoded by a gene located on human chromosome 11q13.1 and mouse chromosome 19 A.
Also known as:
Alternative namesFIGLER6; Anti-LRFN4抗體leucine rich repeat and fibronectin type III domain containing 4; fibronectin type III, immunoglobulin and leucine rich repeat domains 6; Leucine-rich repeat and fibronectin type-III domain-containing protein 4; Lrfn4; LRFN4_HUMAN; MGC3103; SALM3.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Sheep, .
●
Immunogen: KLH conjugated Anti-LRFN4抗體synthetic peptide derived from human LRFN4.
●
Predicted Molecular Weight: 65kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-LRFN4抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
